Want to see JP:3840 full AI Analyst Report?
PATH Corporation (3840) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ivt Gbs-06 | Group B Streptococcal Infections | phase1AndPhase2 | Active Not Recruiting | Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age. | Sep 23, 2024 | ― |
| Non-Adjuvanted Study Formulation Nmcv-5, Adjuvanted Study Formulation Nmcv-5, Menactra | Meningitis, Meningococcal | Phase II | Completed | Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds | Sep 20, 2017 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ivt Gbs-06 | phase1AndPhase2 | Group B Streptococcal Infections | Active Not Recruiting | Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age. | Sep 23, 2024 | ― |
| Non-Adjuvanted Study Formulation Nmcv-5, Adjuvanted Study Formulation Nmcv-5, Menactra | Phase II | Meningitis, Meningococcal | Completed | Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds | Sep 20, 2017 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does PATH Corporation (JP:3840) have in its pipeline
PATH Corporation JP:3840 is currently developing the following drugs: Ivt Gbs-06, Non-Adjuvanted Study Formulation Nmcv-5, Adjuvanted Study Formulation Nmcv-5, Menactra. These drug candidates are in various stages of clinical development as the company works toward FDA approval.